1. Pink Sheet
  2. >>Compliance
  3. >>Marketing & Advertising

In Brief

FDA probes AeroShot energy canister; state cannot force pharmacists to provide Plan B; analysts boost Herbalife earnings estimates; consumers allege Gerber makes false probiotics claims; more news In Brief.

FDA investigates Breathable Foods’just-launched AeroShot Pure Energy after Sen. Chuck Schumer raised concerns about the product to Commissioner Margaret Hamburg. The New York Democrat said children likely will abuse the canister product, which releases a puff of quickly dissolving caffeine powder into the user’s mouth ([A#05120206002]). Breathable Foods CEO Tom Hadfield said in a Feb. 19 statement the Cambridge, Mass., firm is confident of AeroShot’s regulatory compliance and is cooperating with FDA’s review. In a December letter to Hamburg, Schumer said AeroShot “seems well on its way to being marketed to encourage use by young adults in conjunction with alcohol.” He also urged FDA to request data on the effects of inhalable caffeine on people aged 12 to 20.

Washington state cannot force pharmacists to provide OTC emergency contraception to consumers in violation of their religious beliefs, a federal...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

‘Sex Pill For Women’: Sprout CEO’s Addyi Instagram Post Draws US FDA Warning Letter

 
• By Sue Sutter

Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.

Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

 
• By Sue Sutter

Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.

Pharma DTC Ad Tax Break Targeted By US HHS, Congress

 
• By Derrick Gingery

Health and Human Services Secretary Robert F. Kennedy Jr. said a policy that would remove the tax write-off for pharma advertising expenses would be coming in a few weeks.

Sarfez Pharma’s Promotional Claims For Diuretic Soaanz Draw US FDA Warning Letter

 
• By Sue Sutter

Webpages, a healthcare professional pamphlet and a medical conference exhibit booth panel make unsupported comparative superiority claims about generic torsemide products and misrepresent risks, the Office of Prescription Drug Promotion says in its first warning letter of 2025.

More from Compliance

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says

 
• By Cathy Kelly

The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.

US FDA’s Familiar Drug Pricing To-Do List

 
• By Michael McCaughan

President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.